Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
The Micturition Reflex01:26

The Micturition Reflex

606
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
606
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

438
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
438
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

746
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
746
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a core set of outcome measures for OAB treatment.

International urogynecology journal·2017
Same author

Clinical application of IUGA/ICS classification system for mesh erosion.

Neurourology and urodynamics·2015
Same author

Periurethral aggressive angiomyxoma: a case report.

International urogynecology journal·2012
See all related articles

Related Experiment Video

Updated: Jun 30, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K

Overactive Bladder Medication Access.

Yanghee Courbron1, Caroline Foust-Wright

  • 1From the Maine Medical Partners, Pelvic Medicine and Reconstructive Surgery, South, Portland, ME.

Urogynecology (Philadelphia, Pa.)
|March 14, 2024
PubMed
Summary
This summary is machine-generated.

Improving access to overactive bladder medications is crucial. A cost-navigation guide improved patient persistence with prescribed treatments, demonstrating the impact of addressing financial barriers.

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

Related Experiment Videos

Last Updated: Jun 30, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

Area of Science:

  • Urogynecology
  • Pharmacoeconomics
  • Patient Adherence

Background:

  • Overactive bladder (OAB) medications vary widely in cost, insurance coverage, and side effect profiles.
  • Patient access and adherence to OAB pharmacotherapy are often hindered by financial and logistical barriers.
  • A quality improvement initiative aimed to enhance patient access to and adherence with preferred OAB medications.

Purpose of the Study:

  • To increase the proportion of patients receiving their preferred OAB medication monthly from 39.5% to 45% within an academic Urogynecology practice.
  • To identify and address barriers to medication access and persistence in patients with overactive bladder.
  • To evaluate the impact of a targeted intervention on improving medication access and adherence.

Main Methods:

  • Data on medication access and adherence were collected through electronic health records (Epic), chart reviews, and patient/pharmacy calls.
  • A cost-navigation guide was developed and implemented to assist patients in managing prescription expenses.
  • The intervention involved embedding the guide into post-visit summaries within the electronic health record.
  • A pre- and post-intervention analysis was conducted to assess changes in medication persistence.

Main Results:

  • The primary barrier to OAB medication access was identified as cost, including lack of insurance coverage and failure to initiate prior authorizations.
  • Prior to the intervention, over 60% of patients discontinued their initially prescribed OAB medication within 6 months.
  • Following the implementation of the cost-navigation guide, medication persistence improved to 45.5% at a 3-month follow-up interval.

Conclusions:

  • Targeted interventions focused on prescription cost navigation can significantly improve patient access to and persistence with overactive bladder medications.
  • The developed cost-navigation guide proved effective in mitigating financial barriers to OAB pharmacotherapy.
  • The practice continues to utilize the prescription navigation handout to support patient adherence and access to care.